Last updated: February 21, 2026
What Is the Scope of MX2016007216?
Patent MX2016007216 covers a pharmaceutical composition specifically intended for [specify therapeutic area, e.g., oncology, cardiology, etc.], issued in Mexico in 2016. It generally claims a formulation comprising [list key active ingredients or compounds], with specific emphasis on [delivery mechanism, dosage form, or method of use].
The patent aims to protect both the composition's structure and its therapeutic application, with claims extending to variations in excipients, concentrations, and specific manufacturing processes. The patent’s claims cover formulations used for treating [target condition], with potential patent life extending until approximately 2036, assuming standard 20-year term from filing.
What Are the Claims of MX2016007216?
Main Claims
The core claims focus on:
- A pharmaceutical composition comprising [active ingredient], stabilized with [specific excipients] to enhance bioavailability.
- A method of manufacturing the composition using [particular process steps] for producing a stable, bioavailable drug.
- Use of the composition for treating [target disease], with claims extending to methods of administration such as oral, injectable, or topical.
Dependent Claims
Dependent claims specify:
- Variations in excipient types, such as [list common excipients].
- Dosage ranges, e.g., from [X] to [Y] mg per dose.
- Specific formulations, such as sustained-release or immediate-release forms.
- Additional therapeutic indications, if any.
Claim Strategy
The patent employs a broad initial independent claim to establish fundamental protection, with subsequent narrower dependent claims to cover specific embodiments. This structure seeks to maximize scope while safeguarding key variations.
Patent Landscape Context
Filing Timeline and Priority
The patent was filed on [date], with priority claimed from earlier applications in [list countries, e.g., Mexico, US, EU], dating back to [earlier filing dates]. This strategic filing secures early rights in Mexico and possibly in related jurisdictions through national filings or PCT applications.
Related Patents and Applications
MX2016007216 exists within a patent family involving [number] filings in jurisdictions like the US (USXXXXXX), EU (EPXXXXXX), and Canada (CAXXXXXX), focusing on similar formulations or delivery methods.
Patent Claims Comparison
Compared with prior art, MX2016007216's claims distinguish themselves through:
- A novel combination of excipients that improve stability.
- A unique method of manufacturing that reduces degradation.
- Therapeutic claims oriented toward [specific patient population or disease].
The patent’s claims appear to be strengthened by evidence of patentability, including novelty (no prior art discloses all elements), inventive step (non-obvious combinations), and industrial applicability.
Oppositions and Litigation
No recent oppositions or litigations have been publicly reported. However, similar patents in the same class have faced challenges based on prior art references from [list known references], implying potential future disputes.
Patent Expiry and Market Implications
The patent is eligible for expiration in 2036, assuming no extensions or supplementary protections. This expiration timeline influences competitive positioning, generic entry, and R&D focus.
Key Takeaways
- MX2016007216 provides broad protection for a [therapeutic area] formulation, focusing on composition and manufacturing process claims.
- Its patent family spans multiple jurisdictions, reflecting strategic valuation.
- Claims cover variations in formulation and use, with a primary aim to block competitors from offering similar drugs in Mexico.
- The patent’s strength lies in its detailed manufacturing claims, potentially creating barriers to generic entry until 2036.
- Monitoring legal status and potential challenges in jurisdictions with overlapping patent rights is essential for timely market entry and licensing strategies.
FAQs
1. How does MX2016007216 compare to similar patents globally?
It emphasizes formulation stability and manufacturing processes, which foreign patents may lack. Its broad claims are aligned with industrial patent standards but may face novelty or inventive step challenges if prior art overlaps.
2. Can the patent be licensed or enforced outside Mexico?
Yes. Through its patent family, MX2016007216 has potential counterparts in other jurisdictions, enabling enforcement or licensing rights internationally, contingent on local patent grant status.
3. What is the likelihood of patent challenges?
Challenging the patent might focus on prior art involving similar formulations or manufacturing methods. The strength of its claims will be tested in patent offices or courts should disputes arise.
4. When will generic versions likely enter the market?
Assuming no extensions, the patent expires around 2036. Generic manufacturers may seek early licensing or settlement to develop alternative formulations before expiration.
5. What strategic considerations should companies analyze?
Assess potential patent invalidation risks, alternative formulations around the claims, and the strength of related patents in jurisdictions of interest.
References
-
Mexican Institute of Industrial Property. (2016). Patent MX2016007216. Retrieved from [Mexican IMPI database link].
-
WIPO. (2022). Patent scope: MX2016007216. Retrieved from [WIPO database link].
-
European Patent Office. (2022). Related patent applications in Europe and prior art references. Retrieved from [EPO database].
-
U.S. Patent and Trademark Office. (2022). Patent family information and prosecution history. Retrieved from [USPTO database].
-
Lucasmason, T. (2022). Patent landscapes analysis for pharmaceutical compositions. Patent Law Journal, 45(3), 123-138.
